Company intelligence / Profile preview

CDx Diagnostics

Suffern, New York, United Statesfacebook.com ↗

Ownership: Private
Development stage: Commercial

Overview

CDx Diagnostics has commercialized its WATS3D AI-powered diagnostic platform for early detection of esophageal and oral precancers/cancers. The company reports that routine clinical use has already detected thousands of otherwise-missed cases. It continues to adapt its technology to additional GI cancers including bile duct, stomach, and colon. Clinical studies are ongoing or planned for these new indications.

Therapeutic areas: OncologyGastroenterology
Modalities: Device (diagnostic platform)Artificial intelligence-based diagnosticsMolecular biology-based diagnosticsCytopathology-based diagnosticsImaging technology (3D imaging)
Industry: Pathology

Partnerships

None specifically listed.

Beyond the preview

Go deeper on CDx Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CDx Diagnostics.

Explore the full profile